Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

Sanofi post­ed a strong set of first-quar­ter re­sults Thurs­day morn­ing, with its re­com­bi­nant fac­tor drug Al­tuvi­i­io on track to be­come a block­buster drug and its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER